Mo Elzek

x.com/i/article/2022…

How could tiny breakthroughs in aging science change U.S. GDP and population growth? What’s the economic value of making 41 the new 40, or 65 the new 60? How many lives could we create or save if we could slow reproductive or brain aging by just 1 year? What would billions of healthier hours be worth to the economy, if we assume no change in the age of retirement? I spent the last two years obsessing over the design, research, and execution of this project. The result is a book upcoming with Harvard University Press, a preprint, and—maybe your favorite part—an interactive simulation tool that lets you input your own timelines and assumptions for specific breakthroughs in aging bio, then see the ROI in terms of US population & GDP growth. From @RickEcon and Jason DeBacker—the economists who co-developed the open-source, macro model that made this project possible—to extensive comments by @tylercowen, @sapinker, Richard Freeman, @NDHendrix, @ebudish, @elidourado, @geochurch, @jasoncrawford as well as interviews with 102 scientists (!) and countless iterations with award-winning designer Giorgia Lupi and the @pentagram team, we built something we hope will be a benchmark for how scientists, economists, designers, philosophers, entrepreneurs and storytellers can come together to paint, fund, and build different flourishing futures for our species. I couldn’t be more excited to share this. It’s the start of an open and evolving project—the labor and product of love, obsession, and unrelenting care. I hope you have fun playing with our simulation tool — and if you do, please share!

Compare pharma to tech, where the founder is the protagonist. They have a face, a name, and an authentic connection to a product/service, which millions of people are know by name. Jensen Huang *is* Nvidia. Pharma doesn't work this way. Most people can't name three drugs nor their makers. And the CEO, typically not the founder, can't be the product the way a tech founder can. Dave Ricks went on the Cheeky Pint podcast talking like a real person, something unusual for a pharma CEO. The response on Twitter was overwhelmingly positive, because people saw a human making decisions instead of a faceless corporation. x.com/collision/stat… Part of why this worked is that Ricks is CEO of Eli Lilly, the company behind Mounjaro. GLP-1s are the closest pharma has to a successful "consumer product”, one that people know by name. Here, a pharma CEO had something to be the face of, the way tech founders do routinely.

Systematic identification of single transcription factor perturbations that drive cellular and tissue rejuvenation pnas.org/doi/full/10.10…

A few days ago it was @OpenAI, now @Anthropic. The others soon. The push into healthcare anthropic.com/news/healthcar…

Today in @NatureMedicine we report that AI can predict 130 diseases from 1 night of sleep🛌 We trained a foundation model (#SleepFM) on 585K hours of sleep recordings from 65K people—brain, heart, muscle & breathing signals combined. AI learns the language of sleep🧵